WuXi Advanced Therapies Revenue and Competitors

Claim your profile

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • WuXi Advanced Therapies's estimated annual revenue is currently $72.8M per year.(i)
  • WuXi Advanced Therapies's estimated revenue per employee is $155,000

Employee Data

  • WuXi Advanced Therapies has 470 Employees.(i)
  • WuXi Advanced Therapies grew their employee count by 6% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4180M1816513%$550M$18.5B
#2
$19.8M128-57%N/AN/A

Accelerating the Progress and Time to Market of Bio-Based Drugs through Integrated Manufacturing and Laboratory Testing Services Our Story By leveraging platforms and integrated testing, the Advanced Therapies business unit of WuXi AppTec is a streamlined Contract Development and Manufacturing Organization (CDMO), pioneering the expedited development and commercialization of cell, gene, protein and viral-based therapies. This approach enables new biopharmaceuticals to be developed, manufactured and released faster and with greater predictability, thereby reducing the complexities of high-touch, multi-vendor production models. Our solutions help clients overcome challenges to commercialization, including process development, manufacturing capacity, analytical development, and raw materials management. Multiple, scale-able, enabling platforms integrate manufacturing, process development and testing capabilities to provide greater predictability and speed to clinic. Well positioned for growth, our investments in personnel and manufacturing continue to expand clinical and commercial capacities. Since 2004, WuXi AppTec has supported Advanced Therapy programs with an extensive infrastructure of state-of-the-art, GMP-compliant facilities, providing centers of excellence for manufacturing and testing. Our Vision To significantly contribute to the growth of Advanced Therapies by accelerating and transforming development and manufacturing through our enabling platforms and technologies to the benefit of patients worldwide.

keywords:Biotechnology,Healthcare,Pharmaceuticals

N/A

Total Funding

470

Number of Employees

$72.8M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

WuXi Advanced Therapies News

2022-04-20 - WuXi Advanced Therapies teams with Singapore group on cell ...

The CDMO unit of Wuxi AppTec, WuXi ATU, is partnering with a Singapore research group to advance cell and gene therapy manufacturing in the Asia...

2022-04-20 - WuXi Advanced Therapies and A*

WuXi Advanced Therapies and A*STAR announce partnership to advance cell and gene therapy in the Asia-Pacific region.

2022-04-20 - WuXi Advanced Therapies and A*STAR announce partnership to ...

SINGAPORE, April 28, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, and A*STAR's...

2019-09-03 - Going Viral: The Next Generation of AAV Vectors

The safe delivery of genetic cargo has preoccupied gene therapy for at .... the Chinese company WuXi Advanced Therapies, Novasep, Vigene ...

2019-09-03 - WuXi AppTec Launches DNA Encoded Library (DEL) Service ...

3, 2019 /PRNewswire/ -- WuXi AppTec today announced its launch of ... to advance discoveries and deliver groundbreaking treatments to ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$58.8M470-3%N/A
#2
$106.2M472N/AN/A
#3
$159.3M4728%N/A
#4
$121.5M47419%N/A
#5
$161M47730%N/A